[INQ. NO. 2203C02] A biosimilar is a medicine that is structurally identical to a bio-bio-engineered drug with its safety verified through clinical trials.
Peptide medicine is a kind of biopharmaceutical, for which demand is gradually increasing due to its efficacy against various diseases — ranging from adult diseases such as obesity and diabetes, to rare diseases based on low side effects and excellent efficacy.
PEPGENE is a biopharmaceutical specialist that develops biosimilar production technology for peptide medicine, to increase the business viability of biosimilar products, which is high-growth business content. The company is taking the lead in popularizing the treatment of metabolic and rare diseases using this special technology.
PEPGENE manufactures recombinant cells suitable for the production of peptide medicine by improving cells to meet various requirements such as cell growth and production of peptide medicine.
Through intensive R&D of the production process through selected strains, PEPGENE cultivates strains under various conditions, produces peptide drugs, and adjusts refining yield, as well as optimizes and minimizes the process.
It has developed the most optimized protocol for mass production based on the company’s research and development background.
PEPGENE aims to continue developing and supplying biosimilar production technology for peptide and protein pharmaceuticals with proven efficacy and marketability ─ by securing high production yield based on excellent peptide recombinant production base technology.
Korean-Products.com | Blog Magazine of Korean products, brands and Goods
